By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


GlycoMimetics, Inc. 

14915 Broschart Road, Suite 200

Rockville   Maryland  20850  U.S.A.
Phone: 301-738-1166 Fax:




Company News
GlycoMimetics, Inc. (GLYC) Doses First Patient In Phase 2 Portion Of Clinical Trial Of GMI-1271 In Newly Diagnosed Acute Myeloid Leukemia 6/28/2016 10:22:05 AM
GlycoMimetics, Inc. (GLYC) Announces Proposed Public Offering Of Common Stock 6/17/2016 10:02:20 AM
GlycoMimetics, Inc. (GLYC) Announces Pricing Of Public Offering Of Common Stock 6/17/2016 8:18:49 AM
GlycoMimetics, Inc. (GLYC)’ GMI-1271 Receives FDA Fast Track Designation For Treatment Of Acute Myeloid Leukemia 6/13/2016 8:19:15 AM
GlycoMimetics, Inc. (GLYC)’ GMI-1271 Yields High Remission Rates And Favorable Tolerability In Phase I Portion Of Phase I/II Clinical Trial For AML 6/10/2016 8:28:06 AM
GlycoMimetics, Inc. (GLYC) Doses First Patient In Phase II Portion Of GMI-1271 Clinical Trial In Relapsed/Refractory Acute Myeloid Leukemia 6/6/2016 8:11:11 AM
GlycoMimetics, Inc. (GLYC) To Present At Jefferies 2016 Healthcare Conference 6/2/2016 10:32:29 AM
GlycoMimetics, Inc. (GLYC) Announces Publication Of New Preclinical Data With GMI-1271 In Science Translational Medicine 5/26/2016 11:39:01 AM
3 Biotech Stocks Flying High Under-the-Radar 5/26/2016 6:31:07 AM
Initial Efficacy Data For GlycoMimetics, Inc. (GLYC)’ GMI-1271 Combined With Chemotherapy In Patients With AML To Be Presented At European Hematology Association 21st Congress 5/19/2016 12:52:39 PM